Overview

HemaQuest is developing a clinical program to evaluate HQK-1004 in patients with lymphoma or lymphoproliferative disorders (LPD) that are associated with Epstein Barr virus (EBV). Previously, a trial conducted by Drs. Faller and Perrine was published in the leading hematology journal, Blood, which showed promising clinical results in patients with these serious and life-threatening diseases. In this trial, 10 out of 15 patients with relapsed or refractory disease demonstrated objective tumor responses to a 3 week treatment with HQK-1004 combined with the commonly used anti-viral drug, ganciclovir. The treatment was well-tolerated without the side effects commonly observed with cancer chemotherapy drugs (e.g., marrow suppression).

Further laboratory studies and the rapid tumor responses observed in the initial clinical study suggested that a more abbreviated course of therapy may also be effective. Therefore, a 5-day HQK-1004 treatment regimen is now being evaluated in a similar patient population in a multicenter trial as described below.

Phase 2 Clinical Trial – Closed to Enrollment

Trial Title: A Phase II Trial of Low-Dose HQK-1004 and Ganciclovir/Valganciclovir in EBV (+) Lymphoid Malignancies

This trial is designed to test the effectiveness of up to three, 3-week treatment cycles consisting of HQK-1004 given for 5 days with ganciclovir and valganciclovir administered for 21 days in patients with EBV+ lymphomas and lymphoproliferative disorders. This trial is being conducted at Hackensack University Medical Center in Hackensack, New Jersey.

More information can be found at www.clinicaltrials.gov or by emailing info@hemaquest.com

Phase 2 Multicenter Trial – Currently Enrolling Patients

Trial Title: A Phase 2a Open-Label Multi-Center Study Evaluating HQK-1004 Administered with Ganciclovir and Valganciclovir in Patients with Relapsed or Refractory Epstein-Barr Virus Positive Lymphoid Malignancies or Lymphoproliferative Disorders

This trial is designed to test the effectiveness of up to six 3-week treatment cycles consisting of HQK-1004 given for 5 days with IV ganciclovir. Oral valganciclovir will be administered for the remaining 16 days of each 3-week cycle in patients with EBV+ lymphomas and lymphoproliferative disorders. Participants, ages 3 and older, must have previously had a tumor biopsy that was positive for EBV or can now be tested for EBV and should have tumor(s) that are measurable from a radiographic image.

More information on this study and on participating centers can be found at www.clinicaltrials.gov or email: info@hemaquest.com